Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y., . . . Bannerji, R. (2013). A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. BioMed Central.

Nemunaitis, John J., Karen A. Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao, and Rajat Bannerji. A First-in-human, Phase 1, Dose-escalation Study of Dinaciclib, a Novel Cyclin-dependent Kinase Inhibitor, Administered Weekly in Subjects With Advanced Malignancies. BioMed Central, 2013.

Nemunaitis, John J., et al. A First-in-human, Phase 1, Dose-escalation Study of Dinaciclib, a Novel Cyclin-dependent Kinase Inhibitor, Administered Weekly in Subjects With Advanced Malignancies. BioMed Central, 2013.